We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Stock Moves -1.58%: What You Should Know
Read MoreHide Full Article
Pfizer (PFE - Free Report) closed at $43.11 in the latest trading session, marking a -1.58% move from the prior day. This change was narrower than the S&P 500's daily loss of 2.08%. Meanwhile, the Dow lost 2.11%, and the Nasdaq, a tech-heavy index, lost 2.27%.
Heading into today, shares of the drugmaker had gained 1.37% over the past month, outpacing the Medical sector's loss of 1.48% and the S&P 500's loss of 3.6% in that time.
PFE will be looking to display strength as it nears its next earnings release, which is expected to be January 29, 2019. On that day, PFE is projected to report earnings of $0.64 per share, which would represent year-over-year growth of 3.23%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $13.73 billion, up 0.18% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $3 per share and revenue of $53.40 billion, which would represent changes of +13.21% and +1.62%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for PFE. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. PFE is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that PFE has a Forward P/E ratio of 14.61 right now. This represents a premium compared to its industry's average Forward P/E of 14.42.
Also, we should mention that PFE has a PEG ratio of 2.18. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.04 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 62, putting it in the top 24% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow PFE in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Stock Moves -1.58%: What You Should Know
Pfizer (PFE - Free Report) closed at $43.11 in the latest trading session, marking a -1.58% move from the prior day. This change was narrower than the S&P 500's daily loss of 2.08%. Meanwhile, the Dow lost 2.11%, and the Nasdaq, a tech-heavy index, lost 2.27%.
Heading into today, shares of the drugmaker had gained 1.37% over the past month, outpacing the Medical sector's loss of 1.48% and the S&P 500's loss of 3.6% in that time.
PFE will be looking to display strength as it nears its next earnings release, which is expected to be January 29, 2019. On that day, PFE is projected to report earnings of $0.64 per share, which would represent year-over-year growth of 3.23%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $13.73 billion, up 0.18% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $3 per share and revenue of $53.40 billion, which would represent changes of +13.21% and +1.62%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for PFE. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. PFE is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that PFE has a Forward P/E ratio of 14.61 right now. This represents a premium compared to its industry's average Forward P/E of 14.42.
Also, we should mention that PFE has a PEG ratio of 2.18. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.04 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 62, putting it in the top 24% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow PFE in the coming trading sessions, be sure to utilize Zacks.com.